Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment

Biomedicines

Yilong Zhang²  Rajul K. Jain¹  Min Zhu² 

[1] Kite Pharma, Inc., 2225 Colorado Avenue, Santa Monica, CA 90404, USA; E-Mail:;Department of Clinical Pharmacology, Modeling and Simulation, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA; E-Mail:

关键词: HGF;    MET;    cancer treatment;    new therapeutic agents;    biomarker;   

DOI  :  10.3390/biomedicines3010149

来源: mdpi

【 摘 要 】

The hepatocyte growth factor (HGF): MET axis is a ligand-mediated receptor tyrosine kinase pathway that is involved in multiple cellular functions, including proliferation, survival, motility, and morphogenesis. Aberrancy in the HGF/MET pathway has been reported in multiple tumor types and is associated with tumor stage and prognosis. Thus, targeting the HGF/MET pathway has become a potential therapeutic strategy in oncology development in the last two decades. A number of novel therapeutic agents—either as therapeutic proteins or small molecules that target the HGF/MET pathway—have been tested in patients with different tumor types in clinical studies. In this review, recent progress in HGF/MET pathway-targeted therapy for cancer treatment, the therapeutic potential of HGF/MET-targeted agents, and challenges in the development of such agents will be discussed.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.